Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases
CONCLUSION: There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety. To provide further evidence, future studies using more precise dose-escalation protocols are warranted.PMID:38563202 | DOI:10.1080/03009742.2024.2327159
Source: Scandinavian Journal of Rheumatology - Category: Rheumatology Authors: M Ayano K Tsubouchi K Suzuki Y Kimoto Y Arinobu K Akashi T Horiuchi I Okamoto H Niiro Source Type: research
More News: Arthritis | Interstitial Lung Disease | PET Scan | Rheumatoid Arthritis | Rheumatology | Scleroderma | Study | Women